Features
Is There a Role for SLT After MIGS?
A practical framework for patient selection and clinical decision-making when intraocular pressure rises after minimally invasive glaucoma surgery.
By Shivani S. Kamat, MD
Predicting Success After Angle Surgery
Clinical clues, imaging biomarkers, and genetics may help identify the patients most likely to benefit from angle-based MIGS.
By Si Jia Chen, BS, Arsham Sheybani, MD
Procedural Pharmaceutical Lessons From Early Adopters
Experienced glaucoma surgeons share practical pearls on integrating sustained drug delivery into practice.
By Christine Funke, MD, J. Morgan Micheletti, MD, FACS, Jason Bacharach, MD, et al.
Perspectives on Medicare’s Proposed iDose TR Coverage Policy
Six glaucoma specialists discuss Medicare's proposed local coverage determinations (LCDs) for iDose TR and how they could affect patient care.
By Steven R. Sarkisian, Jr., MD, Inder Paul Singh, MD, Savak “Sev” Teymoorian, MD, MBA, et al.
Beyond Today’s Implants: The Next Generation of Sustained Drug Delivery
The investigational pipeline is moving to address challenging questions of treatment duration, repeatability, and clinical integration.
By Ciera D. Johnson, BS, Rachel Chapman, Samantha Goldburg, MD, et al.
Web Exclusives
Revisiting Strategies for Glaucoma Education
Improve patient adherence and outcomes with these simple tips.
By Inder Paul Singh, MD
Departments
The Prevention Paradox
From the Editor
Glaucoma treatment asks patients, physicians, and payers to act before the consequences are visible.
By Nathan Radcliffe, MD
Letter to Editor and Response
Concern Regarding Coding Guidance and Relevant Financial Disclosures
By Sean Ianchulev, MD, MPH, Kevin J. Corcoran, COE, FNAO
Glaucoma Trials Tracker
Access Glaucoma Physician's listing of all active interventional clinical trials related to glaucoma.